1. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Issue 1 (28th June 2012) Authors: Rossi, S.; Motta, C.; Studer, V.; De Chiara, V.; Barbieri, F.; Monteleone, F.; Fornasiero, A.; Coarelli, G.; Bernardi, G.; Cutter, G.; Stüve, O.; Salvetti, M.; Centonze, D. Journal: European journal of neurology Issue: Volume 20:Issue 1(2013:Jan.) Page Start: 87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Monoclonal antibodies in treatment of multiple sclerosis. (4th February 2014) Authors: Rommer, P. S.; Dudesek, A.; Stüve, O.; Zettl, U.K. Journal: Clinical and experimental immunology Issue: Volume 175:Number 3(2014:Mar.) Page Start: 373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Neuroinflammation of the central and peripheral nervous system: an update. (4th February 2014) Authors: Stüve, O.; Zettl, U. Journal: Clinical and experimental immunology Issue: Volume 175:Number 3(2014:Mar.) Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. (4th February 2014) Authors: Rommer, P. S.; Zettl, U. K.; Kieseier, B.; Hartung, H.‐P.; Menge, T.; Frohman, E.; Greenberg, B. M.; Hemmer, B.; Stüve, O. Journal: Clinical and experimental immunology Issue: Volume 175:Number 3(2014:Mar.) Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗